PPARG and myeloid sarcoma: Together, these data demonstrated that PPARγ played an important role in regulating autoimmune encephalomyelitis in vivo and suggested that PPARγ agonists might be a new therapeutic treatment for autoimmune demyelinating diseases such as MS.